RxDoctor Payments Data

Ruth Santos Rodriguez, MD

Pulmonary Disease · San Juan, PRNPI 1508083320

Payments from drug & device makers

$1,438in general payments, 2019–2025

Across 36 payments — averaging $39.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$199
  • AstraZeneca$192
  • GSK$181
  • Boehringer Ingelheim$160
  • Genentech USA, Inc.$157
  • Sanofi$121
  • plus $429 from 9 others

What the payments were for

  • Food & beverage$1,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,438 in reported general payments places this provider in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,878
Medicare patients
20
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,360
Breo ElliptaFluticasone/Vilanterol20$8,257
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$6,931
Albuterol Sulfate HfaAlbuterol Sulfate120$4,808
Azelastine-FluticasoneAzelastine/Fluticasone14$1,459
Fluticasone Propionate54$941
Levalbuterol Tartrate HfaLevalbuterol Tartrate14$868
Montelukast Sodium44$510
Famotidine36$323
Pantoprazole Sodium26$278
Azithromycin24$183
Methylprednisolone19$158
Prednisone33$109
Rosuvastatin Calcium12$63
Omeprazole11$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$181$41,61770 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →